Stem Cell Research, PTV News: May 13, 2010

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Stem Cell Research, PTV News: May 13, 2010
Released on: May 13, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Follow us:
  • Summary
  • Transcript
  • Participants
  • Company
Mesoblast snaps up Angioblast shares in a deal over Stem Cell therapies which could generate 500 million dollars a year
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Adrian Dawkes
Senior Director

Adrian has significant multi-discipline expertise spanning research & development through to sales, marketing and business development from 25 years in the pharmaceutical, biotechnology and in vitro diagnostics sectors. Adrian has held senior positions with Johnson & Johnson, drug discovery platform company Acumen Bioscience and the Healthcare Consultancy company Execute Technologies. Adrian has a BSc in Biochemistry and a PhD in Immunochemistry from Oxford Brookes.
Angioblast Systems
Angioblast Systems, Inc. is a privately held biotechnology company. Angioblast develops and commericalises novel therapeutic products for the treatment of cardiovascular diseases and vascular disorders.
Mesoblast Limited an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the commercialisation of unique adult stem cells to regenerate and repair bone and cartilage.
PharmaVentures Ltd
PharmaVentures is a company that has proven success in deals and alliances.

PharmaVentures offers:

• Over 18 years of healthcare industry experience

• Experience gained from working with in excess of 1000 clients in 38 countries, and conducting more than 450 assignments

• Over 40 specialist advisors, analysts and researchers

• Skills honed in many countries - 80% of its business comes from outside the UK